Corrigendum to "Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study" [Journal of Critical Care 52 (2019) 75-79]
1 Department of Intensive Care Medicine, Ghent University Hospital, Ghent, Belgium. Electronic address: sofie.dhaese@ugent.be.
2 Ghent University, Ghent, Belgium.
3 Department of Pharmacy, Mount Sinai West Hospital, New York, United States.
4 University of Queensland Centre for Clinical Research, The University of Queensland, Brisbane, Australia; Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia.
5 Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium; Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.
6 University of Queensland Centre for Clinical Research, The University of Queensland, Brisbane, Australia; Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia; Department of Pharmacy, Royal Brisbane and Women's Hospital, Brisbane, Australia; Centre for Translational Anti-infective Pharmacodynamics, School of Pharmacy, The University of Queensland, Brisbane, Australia.
7 Department of Intensive Care Medicine, Ghent University Hospital, Ghent, Belgium.